CannabisNewsBreaks

TuesdayAug 20, 2024 11:13 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

Continue Reading

ThursdayAug 15, 2024 11:34 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports on Voting Results of 2024 Annual and Special Meeting of Shareholders

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, is reporting on its 2024 Annual and Special Meeting of Shareholders. The meeting. According to the announcement, shareholders voted on and approved all five proposals on the agenda. Proposals included the election of four directors to the company’s board of directors; the reappointment of Davidson & Company LLP, an independent registered public accounting firm, as the company auditors; amending FLGC’s Incentive Compensation Plan to increase the issuable number of shares; granting stock appreciation rights to the company's CEO and CFO; and issuing 635,363 shares in accordance with NASDAQ guidelines…

Continue Reading

TuesdayAug 06, 2024 1:30 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting recent results from its WEIGHT-A24-1 animal study. A recent article notes that interim results, which are based on the first 28 days of dosing, are “noteworthy,” including all animals showing either a noticeable decrease in the rate of body weight gain or the beginning of weight reduction. According to the article, the study was designed to the impact of Lexaria’s patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss; the article noted that this study marks a “significant milestone”…

Continue Reading

TuesdayJul 30, 2024 11:44 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and…

Continue Reading

WednesdayJul 17, 2024 2:47 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several noteworthy findings. According to the announcement, unlimited food and water have been provided to the animals for the entire duration of the study. During the initial acclimation phase, which spanned 34 days before the beginning of dosing, the animals gained 10.9% body weight on average. During the subsequent 28 days of DehydraTECH-processed drug therapy dosing, all test…

Continue Reading

TuesdayJul 16, 2024 1:31 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects and initiatives. With that in mind, the company has named Nelson Cabatuan as consulting chief strategic financial advisor; Cabatuan is currently serving as Lexaria CFO. In his new role, Cabatuan will leverage his skills in corporate finance and strategic industry relationships to focus on strategic opportunities. In addition, Lexaria is working on other research and development projects…

Continue Reading

TuesdayJul 09, 2024 2:27 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study arm used a Rybelsus(R) composition processed with DehydraTECH that is compliant with the FDA’s Inactive Ingredient Database (“FDA IID”), delivered within an in-mouth dissolvable tablet. According to the announcement, this will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can absorb at any level systemically through the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective drug delivery into…

Continue Reading

MondayJul 08, 2024 3:45 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. Following an earlier one granted in Canada, this is the company’s second patent in this family. In Canada, Lexaria has received a new patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the company’s fourth granted patent in this family, which was previously granted in the U.S., Australia and Japan. Further, building…

Continue Reading

TuesdayJul 02, 2024 11:02 am

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) CEO Shares Insight into Dynamic Operations, Visionary Goals Through Spaces Event

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced the availability of the replay for its highly anticipated July 1 Spaces event on X.com. The event was hosted by GTV’s CEO, Steffan Dalsgaard, who delivered a complete overview of GTV’s multifaceted business activities, including a key highlight of its flagship Destino Ranch project. During the live session, Dalsgaard provided comprehensive insights into the company’s diverse business, strategic initiatives and ambitious future growth plans. The event garnered significant attention and was met with enthusiasm from shareholders and the general public, offering a rare glimpse into Golden Triangle Ventures’ dynamic operations and visionary…

Continue Reading

ThursdayJun 27, 2024 3:30 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes… The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and…

Continue Reading